Tenmile

AdvanCell is a clinical-stage company developing novel radiopharmaceuticals for cancer treatment. It specializes in attaching alpha-emitting isotopes to molecules that deliver cytotoxic radiation directly to tumors, aiming to provide safe and effective therapies for multiple cancer types.

Proton Intelligence develops a wearable device that monitors potassium levels in real-time via interstitial fluid, closely correlated to blood. This enables clinicians and patients to manage medications and diets effectively for improved heart and kidney care, particularly targeting hyperkalemia in chronic kidney disease patients with co-morbidities.

Xylo Bio is a drug development company focused on next-generation psychedelic-inspired therapeutics for psychiatric and neurological disorders. Through a psychedelic therapeutic platform, it aims to develop non-hallucinogenic, rapid-acting medicines that can be widely available and provide improvements over current SSRI treatments. The company seeks to rewire neural circuits and restore brain function, enabling clinicians to optimize care and expand treatment options beyond traditional antidepressants.

Stamford Pharmaceuticals focuses on developing innovative immunotherapy treatments for primary, recurrent, and metastatic cancers. It employs various technologies, including viral vectors and affinity agents, to deliver biological therapies, aiming to provide advanced treatment options for patients with cancer.

LimmaTech Biologics is a clinical-stage biotechnology company developing vaccines to prevent life-threatening infectious diseases. It uses proprietary platforms for self-adjuvanting and multi-antigen vaccines, focusing on pathogens resistant to current treatments.

Tin Alley Ventures is a venture capital investment firm based in Melbourne, Australia, founded in 2022. The firm focuses on investing in technology startups at various stages, including seed, early, and later stages. It collaborates closely with companies and researchers within the University of Melbourne's ecosystem, aiming to support and develop businesses that have the potential to create significant social and economic impact. Through its strategic partnerships and investment approach, Tin Alley Ventures seeks to foster innovation and drive growth in the technology sector.

Carina Biotech specializes in developing cellular immunotherapies, focusing on treating childhood cancers. They research and develop chimeric antigen receptor T cell (CAR-T) therapies to target solid tumors, aiming to improve access and infiltration of cancer cells while enhancing CAR-T cell manufacturing.

Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Emyria Limited is a healthcare technology and services company based in West Leederville, Australia. Founded in 2018, it operates a network of specialist medical clinics that provide patient-focused treatments, including cannabinoid-based medicines. Emyria is committed to advancing treatment development and enhancing patient care through data-driven approaches. The company has also established a partnership with Mind Medicine Australia to co-develop a clinical model for the safe provision of psychedelic-assisted therapies in Australia. Emyria, previously known as Emerald Clinics Limited, reflects a dedication to innovative healthcare solutions and evidence-based practices.

Mindset Health is a digital therapeutics company offering a mobile platform that delivers app-based hypnotherapy and psychotherapy to help people manage irritable bowel syndrome and other chronic conditions. The platform can treat IBS without dietary changes, improve sleep, and reduce anxiety, stress, and pain related to chronic conditions, providing a rapid, cost-effective, nonaddictive, and safe alternative to traditional care. Based in Melbourne, Australia, Mindset Health focuses on accessible digital therapies that complement conventional treatment and support mental and physical well-being.

SpeeDx is a company that specializes in molecular diagnostic solutions, offering advanced testing systems that provide comprehensive information for enhanced patient management. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx develops market-leading multiplex detection and priming strategies. Its product portfolio includes diagnostics for sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By focusing on multiplex systems, SpeeDx enables healthcare providers to efficiently test for various infectious diseases and assess antibiotic resistance, thereby improving clinical decision-making and patient outcomes.

CurveBeam AI develops, manufactures, operates, and sells artificial intelligence tools for bone analysis.

Inventia Life Science Pty Ltd is an Australian company founded in 2013 and based in Alexandria. It specializes in 3D bioprinting technology aimed at enhancing cell-based research and clinical applications. The company develops, manufactures, and sells equipment, reagents, and bio-inks—both natural and synthetic—designed for advanced medical research. Inventia's innovative approach focuses on creating low-cost and standardized methods for producing three-dimensional human tissue and organ models. This technology is intended to accelerate cancer research, drug discovery, and advancements in regenerative medicine. By providing a comprehensive suite of hardware, software, consumables, and customized protocols, Inventia Life Science facilitates the flexible production of 3D cell-based assays, significantly impacting the medical research landscape.

Aravax is an early-stage biotechnology company developing peanut allergy therapies. It uses proprietary technology to reset the immune system to tolerate peanuts without triggering allergic reactions, aiming to provide a safe and rapidly effective treatment. The company was founded in 2015 through the acquisition of intellectual property developed by Alfred Health and Monash University and is headquartered in Melbourne, Australia.

Perx Health is a digital care management program focused on enhancing treatment adherence among high-risk members with chronic conditions. Tailored specifically for clinically complex patients, the platform effectively manages various health issues, including diabetes and behavioral health, by employing a range of motivational techniques that address low health literacy. Perx Health's approach integrates reminders, education, and monitoring of medication regimens, while also utilizing gamification and rewards to encourage consistent medication adherence. This innovative strategy has resulted in a remarkable 90% adherence rate, leading to significant clinical improvements in metrics such as HbA1C and cholesterol control. Health plans utilizing Perx Health's services experience substantial cost savings and a high return on investment, underscoring the program's effectiveness in driving patient engagement and improving health outcomes.